益生菌辅助四联疗法对H. pylori感染患者根治效果及肠道菌群的影响

研究益生菌辅助四联疗法对H. pylori感染患者根治效果及肠道菌群的影响。

选择2019年1月至2020年6月在我院接受治疗的160例H. pylori感染患者为研究对象，用随机数字表法分为对照组（n = 80）和观察组（n = 80）。对照组患者给予标准铋剂四联药物治疗，观察组加用双歧杆菌四联活菌片治疗。比较两组患者的H. pylori根除率、复发率、不良反应发生率、临床症状（上腹痛、上腹胀、嗳气、纳差）、肠道菌群（双歧杆菌、乳杆菌）和炎性因子[白细胞介素-6（IL-6）、白细胞介素-8（IL-8）及肿瘤坏死因子-α（TNF-α）]水平。

观察组患者的H. pylori根除率（95.00%）高于对照组（82.5%），复发率和不良反应发生率低于对照组（均P＜0.05）。治疗后两组患者的临床症状积分均显著下降，同时观察组患者上腹痛、上腹胀、嗳气、纳差等临床症状积分低于对照组（均P＜0.05）。治疗后观察组患者肠道双歧杆菌和乳杆菌数量升高，而对照组降低，同时观察组患者肠道双歧杆菌和乳杆菌数量高于对照组（均P＜0.05）。治疗后观察组患者IL-6、IL-8和TNF-α水平均低于对照组（均P＜0.05）。

双歧杆菌四联活菌片辅助标准铋剂四联疗法治疗可显著提高H. pylori感染患者H. pylori根除率，降低复发率和不良反应的发生率，改善肠道菌群分布，减轻患者的临床症状和炎症状态。

Effect of probiotics combined with quadruple drug therapy on the eradication and intestinal flora in patients with H. pylori infection

Objective To observe the effect of probiotics combined with quadruple drug therapy on the eradication and intestinal flora in patients with H. pylori infection. Methods A total of 160 patients with H. pylori infection in our hospital from January 2019 to June 2020 were randomly divided into control group (n = 80) or observation group (n = 80). The control group was treated with standard bismuth quadruple drug, while the observation group was treated with quadruple viable Bifidobacterium tablets. The eradication rate, recurrence rate, incidence of adverse reactions, clinical symptoms (epigastric pain, epigastric distension, belching, anorexia), intestinal flora (Bifidobacterium, Lactobacillus) and inflammatory factors (IL-6, IL-8 and TNF-α) were compared between the two groups. Results The eradication rate of H. pylori in the observation group was higher (95.00% vs 82.5%), while the recurrence rate and incidence of adverse reactions were lower (all P＜0.05). After treatment, the clinical symptom scores in the two groups significantly decreased, and those in the observation group were lower (all P＜0.05). After treatment, the counts of intestinal Bifidobacterium and Lactobacillus in the observation group increased, while those in the control group decreased. The counts of intestinal Bifidobacterium and Lactobacillus in the observation group were higher (all P＜0.05). After treatment, the levels of IL-6, IL-8 and TNF-α in the observation group were lower (P＜0.05). Conclusion Quadruple viable Bifidobacterium tablets combined with standard bismuth quadruple therapy in the treatment of H. pylori infection can significantly improve the eradication rate of H. pylori, reduce the recurrence rate and the incidence of adverse reactions, improve the distribution of intestinal flora, and reduce the clinical symptoms and inflammatory state of patients.